$1.04 Billion is the total value of Rhenman & Partners Asset Management AB's 93 reported holdings in Q2 2024. The portfolio turnover from Q1 2024 to Q2 2024 was 13.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LLY | Sell | LILLY ELI & CO | $42,552,860 | +1.0% | 47,000 | -13.2% | 4.08% | +2.3% |
| REGN | Sell | REGENERON PHARMACEUTICALS | $33,632,960 | +1.9% | 32,000 | -6.7% | 3.23% | +3.2% |
| ABBV | Sell | ABBVIE INC | $32,417,280 | -6.1% | 189,000 | -0.3% | 3.11% | -4.9% |
| THC | Sell | TENET HEALTHCARE CORP | $30,463,870 | -23.7% | 229,000 | -39.7% | 2.92% | -22.7% |
| Sell | PROCEPT BIOROBOTICS CORP | $26,879,600 | +11.7% | 440,000 | -9.7% | 2.58% | +13.2% | |
| BDX | Sell | BECTON DICKINSON & CO | $26,409,230 | -8.0% | 113,000 | -2.6% | 2.54% | -6.8% |
| HCA | Sell | HCA HEALTHCARE INC | $26,344,960 | -21.0% | 82,000 | -18.0% | 2.53% | -20.0% |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $25,310,880 | +7.2% | 54,000 | -4.4% | 2.43% | +8.6% |
| CI | Sell | THE CIGNA GROUP | $24,518,707 | -50.8% | 74,171 | -45.9% | 2.35% | -50.1% |
| MRK | Sell | MERCK & CO. INC | $21,665,000 | -24.9% | 175,000 | -19.9% | 2.08% | -23.9% |
| MCK | Sell | MCKESSON CORP | $17,521,200 | -25.8% | 30,000 | -31.8% | 1.68% | -24.9% |
| NTRA | Sell | NATERA INC | $17,001,530 | -22.5% | 157,000 | -34.6% | 1.63% | -21.5% |
| MDT | Sell | MEDTRONIC PLC | $16,371,680 | -42.2% | 208,000 | -36.0% | 1.57% | -41.5% |
| ABT | Sell | ABBOTT LABS | $15,066,950 | -28.3% | 145,000 | -21.6% | 1.45% | -27.4% |
| DXCM | Sell | DEXCOM INC | $13,265,460 | -30.9% | 117,000 | -15.5% | 1.27% | -30.0% |
| ALHC | Sell | ALIGNMENT HEALTHCARE INC | $12,836,123 | +27.9% | 1,641,448 | -18.9% | 1.23% | +29.5% |
| JAZZ | Sell | JAZZ PHARMACEUTICALS PLC | $12,167,220 | -31.1% | 114,000 | -22.3% | 1.17% | -30.3% |
| AXSM | Sell | AXSOME THERAPEUTICS INC | $10,271,800 | -10.4% | 127,600 | -11.1% | 0.99% | -9.2% |
| MDGL | Sell | MADRIGAL PHARMACEUTICALS INC | $7,424,240 | -23.8% | 26,500 | -27.4% | 0.71% | -22.8% |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $7,378,400 | -47.9% | 920,000 | -3.7% | 0.71% | -47.2% |
| Sell | NUVALENT INC | $6,277,415 | -4.5% | 82,750 | -5.4% | 0.60% | -3.2% | |
| VKTX | Sell | VIKING THERAPEUTICS INC | $6,096,150 | -48.7% | 115,000 | -20.7% | 0.58% | -48.1% |
| EPIX | Sell | ESSA PHARMA INC | $4,239,844 | -45.2% | 806,054 | -11.6% | 0.41% | -44.6% |
| PEN | Sell | PENUMBRA INC | $4,139,310 | -59.7% | 23,000 | -50.0% | 0.40% | -59.2% |
| INSP | Sell | INSPIRE MED SYS INC | $2,275,110 | -74.8% | 17,000 | -59.5% | 0.22% | -74.5% |
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $2,124,952 | -79.7% | 55,395 | -68.9% | 0.20% | -79.5% |
| IMCR | Sell | IMMUNOCORE HLDGS PLCads | $1,975,041 | -61.9% | 58,278 | -26.9% | 0.19% | -61.3% |
| PLRX | Sell | PLIANT THERAPEUTICS INC | $1,292,688 | -40.3% | 120,250 | -17.2% | 0.12% | -39.5% |
| AVTR | Sell | AVANTOR INC | $1,272,000 | -70.9% | 60,000 | -64.9% | 0.12% | -70.5% |
| NARI | Sell | INARI MED INC | $963,000 | -64.4% | 20,000 | -64.6% | 0.09% | -64.2% |
| BRKR | Sell | BRUKER CORP | $382,860 | -79.6% | 6,000 | -70.0% | 0.04% | -79.2% |
| NTLA | Exit | INTELLIA THERAPEUTICS INC | $0 | – | -48,000 | -100.0% | -0.12% | – |
| ALPN | Exit | ALPINE IMMUNE SCIENCES INC | $0 | – | -85,500 | -100.0% | -0.32% | – |
| NVCR | Exit | NOVOCURE LTD | $0 | – | -495,307 | -100.0% | -0.73% | – |
| ZBH | Exit | ZIMMER BIOMET HOLDINGS INC | $0 | – | -67,500 | -100.0% | -0.84% | – |
| SWAV | Exit | SHOCKWAVE MEDICAL INC | $0 | – | -64,000 | -100.0% | -1.98% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 43 | Q2 2024 | 5.1% |
| BIOMARIN PHARMACEUTICAL INC | 43 | Q2 2024 | 5.0% |
| ALKERMES PLC | 43 | Q2 2024 | 3.3% |
| LILLY ELI & CO | 42 | Q2 2024 | 5.8% |
| INTRA-CELLULAR THERAPIES INC | 42 | Q2 2024 | 2.4% |
| VERTEX PHARMACEUTICALS INC | 41 | Q2 2024 | 4.3% |
| REVANCE THERAPEUTICS INC | 41 | Q2 2024 | 0.9% |
| ABBVIE INC | 40 | Q2 2024 | 4.4% |
| CVS HEALTH CORP | 40 | Q4 2023 | 3.5% |
| JAZZ PHARMACEUTICALS PLC | 40 | Q2 2024 | 3.1% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-13 |
| 13F-HR | 2024-08-13 |
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.